Trial · NCT07883447
Intravenous Fish Oil Emulsion in Critically Ill Patients With High Inflammatory Status.
NCT07883447, Phase 2, Recruiting, Lee Zheng Yii
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravenous Fish Oil Emulsion in Critically Ill Patients With High Inflammatory Status. Trials, record NCT07883447. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883447
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravenous Fish Oil Emulsion in Critically Ill Patients With High Inflammatory Status.
- NCT number
- NCT07883447
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 159 participants, estimated
- Lead sponsor
- Lee Zheng Yii
- Conditions
- Critical Illness
- Interventions
- Omegaven (10% fish-oil emulsion; Fresenius-Kabi)
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in blood interleukin-6 (IL-6) concentration from Day 1 to Day 4 | Day 1 (before intervention) and Day 4 after randomization | Blood IL-6 concentration will be measured on Day 1 before the intervention and on Day 4. Change will be calculated as the Day 4 value minus the Day 1 value. |
| Secondary | Area under the blood IL-6 concentration-time curve from Day 1 through Day 4 | Day 1 (before intervention), and day 2, 3 and 4 after randomization | The area under the curve will be calculated from blood IL-6 concentrations obtained from Day 1 before intervention through Day 4. |
| Secondary | Change in blood IL-6 concentration from Day 1 to Day 7 | Day 1 (before intervention) and Day 7 after randomization | Blood IL-6 concentration will be measured on Day 1 before the intervention and on Day 7. Change will be calculated as the Day 7 value minus the Day 1 value. |
| Secondary | Change in blood C-reactive protein (CRP) concentration from Day 1 to Days 4 and 7 | Day 1 (before intervention), Day 4, and Day 7 after randomization | Blood CRP concentration will be measured on Days 1, 4, and 7. Changes at Days 4 and 7 will each be calculated by subtracting the Day 1 value. |
| Secondary | Change in blood interleukin-10 (IL-10) concentration from Day 1 to Days 4 and 7 | Day 1 (before intervention), Day 4, and Day 7 after randomization | Blood IL-10 concentration will be measured on Days 1, 4, and 7. Changes at Days 4 and 7 will each be calculated by subtracting the Day 1 value. |
| Secondary | Change in blood procalcitonin concentration from Day 1 to Days 4 and 7 | Day 1 (before intervention), Day 4, and Day 7 after randomization | Blood procalcitonin concentration will be measured on Days 1, 4, and 7. Changes at Days 4 and 7 will each be calculated by subtracting the Day 1 value. |
| Secondary | Change in Sequential Organ Failure Assessment (SOFA) score from Day 1 to Days 4 and 7 | Day 1 (before intervention), Day 4, and Day 7 after randomization | The SOFA score assesses dysfunction across six organ systems. Total scores range from 0 to 24; higher scores indicate greater organ dysfunction. Changes at Days 4 and 7 will each be calculated by subtracting the Day 1 score. |
| Secondary | Blood concentrations of 58 lipid mediators | Day 1 (before intervention), Day 4, and Day 7 after randomization | Concentrations of the 58 prespecified lipid mediators. The lipid mediators are listed in Table 2 of Hartling et al. Clin Chem Lab Med. 2021;59(11):1811-1823. doi:10.1515/cclm-2021-0644 |
| Secondary | Red blood cell eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) levels | Day 1 (before intervention), Day 4, and Day 7 after randomization | EPA and DHA levels in red blood cells will be measured and reported separately. |
| Secondary | Rectus femoris cross-sectional area measured by ultrasound | Day 1 (before intervention); Day 7 or ICU discharge (whichever comes first); and Day 28 or hospital discharge (whichever comes first) after randomization | Ultrasound will be used to measure the cross-sectional area (cm2) of the rectus femoris muscle at each assessment |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883447
GET https://conductscience.org/api/trials/v1/NCT07883447/registered?page=2